Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Proof-of-concept feasibility study in 20 patients demonstrating technical workflow validation and preliminary dosimetric advantages of a novel functional imaging approach, requiring confirmation in larger, prospective trials before clinical adoption.
Rigorous meta-analysis of 8 RCTs with reconstructed individual patient data and quantitative time-to-benefit modelling provides robust evidence on treatment duration, though findings are primarily analytical rather than from a new primary trial.
A critical synthesis and clinical framework addressing heterogeneous stage III NSCLC management in the perioperative immunotherapy era, integrating recent phase III trial evidence with expert consensus on risk-adapted strategies.
A single case report integrated with bibliometric review and exploratory bioinformatic analysis of gene expression datasets; no clinical trial, no new diagnostic or therapeutic validation, and no quantitative evidence of intervention efficacy beyond one patient's response.
A single case report describing diagnostic misidentification of lung cancer as autoimmune interstitial pneumonia; raises awareness of a pitfall but provides no comparative data or outcome measures to support clinical decision-making.
A structured narrative review synthesizing evidence from 99 foundational studies and clinical documents to provide organized guidance on molecular biomarkers, diagnostic methods, and resistance mechanisms in NSCLC precision oncology, rather than reporting original trial data.
A retrospective multi-centre radiomics study with internal and external validation showing moderate discriminatory performance (AUC 0.790–0.818 on external cohorts) for a clinically relevant surrogate endpoint, but lacking prospective design, hard clinical outcomes, or demonstration of impact on treatment decisions.
Meta-analysis of single-arm cohorts showing encouraging efficacy (ORR 53.9%) and manageable safety, but limited by lack of randomized comparator and reliance on surrogate endpoints; requires confirmatory RCT evidence.